Single-use technologies enable a flexibility and modularity effectively unattainable with more traditional stainless-steel technologies, particularly in upstream bioprocesses. Single-use bioreactors up to 2,000 L are employed largely in preclinical- and clinical-stage bioprocesses to leverage this flexibility. As products reach commercial maturity, scales larger than 2,000 L frequently become desirable to take advantage of economies of scale. With the typical upper limit of single-use bioreactors at 2,000 L, this has traditionally meant transfer to stainless-steel systems. The introduction of the Thermo Fisher DynaDrive 5,000-L single-use bioreactor opens a new paradigm of operation in terms of volume, while providing unprecedented ergonomics and flexibility.

Our whitepaper examines this in details, looking closely at:

• Comparison of SS and SU upstream bioprocessing

• Facility economics.

• Total facility ownership cost.

• True cost of goods

• A new options for biologic manufacturing